A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation

NCT03608501 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business decision (no safety or efficacy concerns)

Conditions

Multiple Myeloma

Interventions

DRUG: Ixazomib
DRUG: Thalidomide
DRUG: Dexamethasone

Sponsor

Takeda